Summary of Key Information:
Reporting Period: Quarter and Financial Year Ended 31st March, 2026
Nature of Filing / Announcement: Outcome of Board Meeting - Audited Financial Results
Audit Opinion:
Qualified Opinion - The auditors issued a qualified opinion due to inability to comment on potential adjustments required for aged receivables and advances over 3 years amounting to approximately ₹10,622 lakh.
Key Financial Highlights [in Lakhs]:
Standalone Results:
Quarter Ended 31.03.2026 vs 31.03.2025:
- Revenue from Operations: ₹2,692.71 vs ₹3,224.58 (↓16.5% YoY)
- Total Income: ₹2,818.91 vs ₹3,324.98 (↓15.2% YoY)
- Net Profit: ₹26.64 vs ₹429.25 (↓93.8% YoY)
- EPS: ₹0.02 vs ₹0.33
Year Ended 31.03.2026 vs 31.03.2025:
- Revenue from Operations: ₹10,877.23 vs ₹9,902.56 (↑9.8% YoY)
- Total Income: ₹11,260.76 vs ₹10,223.10 (↑10.1% YoY)
- Net Profit: ₹403.17 vs ₹81.74 (↑393% YoY)
- EPS: ₹0.31 vs ₹0.06
- Other Equity: ₹4,289.29
- Cash and Cash Equivalents: ₹110.86
- Debt: Short-term borrowings ₹1,283.93, Long-term borrowings ₹568.96, Total debt ₹1,852.89
Consolidated Results:
Year Ended 31.03.2026:
- Revenue from Operations: ₹10,877.23
- Total Income: ₹11,260.76
- Net Profit: ₹416.48 (including share of profit from associate ₹13.31)
- EPS: ₹0.32
- Other Equity: ₹4,302.29
Segment-wise Performance:
The company operates in a single business segment of sale of pharmaceutical products. No separate reportable segments as per Ind AS 108.
Corporate Actions:
No dividends, share splits, bonus issues, buybacks, or capital raising activities announced.
Other Significant Information:
- Investment in associate: ₹500.01 lakh during the year
- Exceptional items: None reported
- No change in accounting policy affecting comparability
- No forward-looking guidance or management outlook provided
- Comparative consolidated financial information not presented for previous periods as consolidation was first applied in Q2 FY26